The main pharmacodynamic characteristics of pirenzepine are briefly reported and the experimental plan of the clinical trial on pirenzepine in peptic ulcer is discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Rational Design of Photochromic Analogues of Tricyclic Drugs.
J Med Chem
July 2021
Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute for Science and Technology (BIST), Barcelona 08028, Spain.
Tricyclic chemical structures are the core of many important drugs targeting all neurotransmitter pathways. These medicines enable effective therapies to treat from peptic ulcer disease to psychiatric disorders. However, when administered systemically, they cause serious adverse effects that limit their use.
View Article and Find Full Text PDF[Antisecretory therapy as a component of hemostasis in acute gastroduodenal ulcer bleedings].
Khirurgiia (Mosk)
October 2005
Results of antisecretory therapy (pyrenzepin, H(2)-blockers, inhibitors of proton pump, octreotid) in 962 patients with acute gastroduodenal ulcer bleedings (AGDUB) were analyzed over 14-years period. Antisecretory treatment in AGDUB has principally different goals and potential depending on risk of bleeding's recurrence and morphological changes in tissue of gastroduodenal ulcer. Antisecretory therapy is the main treatment in high risk of AGDUB recurrence or before urgent surgery.
View Article and Find Full Text PDFPharmacologic properties of selective M1--cholinolytic preparation gastrocepin (pirenzepine), its advantages and disadvantages were analyzed. Special attention is given to cytoprotective effect of gastrocepin, Administration of the preparation in complex therapy for chronic recurrent pancreatitis, prophylaxis and treatment of the stress gastroduodenal ulcers and ulcerative hemorrhage is pathogenetically substantiated.
View Article and Find Full Text PDFAutonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade.
J Cardiovasc Pharmacol
May 2003
Fondazione Salvatore Maugeri, Care and Research Institute, Division of Cardiology, Tradate, Italy.
Experimental and clinical evidence documents the beneficial effects of blocking sympathetic activity and modulating heart rate to reduce risk for lethal events in ischemic heart disease. Beside beta-adrenergic receptor blockade, vagal activation is a meaningful approach but not yet easily attainable. Promising results were shown with low-dose atropine and scopolamine, but no follow-up was done because of significant adverse side effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!